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Malignant pleural mesothelioma (MPM) is an aggressive form of thoracic cancer with poor progno-
sis. While some studies have identiﬁed the molecular alterations associated with MPM, little is
known about their role in MPM. For example, fragile X mental retardation (FMR) gene is
up-regulated in MPM but its role in MPM is unknown. Here, utilizing Drosophila genetics, I investi-
gate the possible role FMRmay be playing in MPM. I provide evidence which suggests that FMR may
contribute to tumorigenesis by up-regulating a matrix metalloprotease (MMP) and by degrading the
basement membrane (BM), both important for tumor metastasis. I also demonstrate a novel link
between FMR and the JNK pathway and suggest that the effects of FMR in MPM could in part be
mediated by up-regulation of the JNK pathway.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Malignant pleural mesothelioma (MPM) is an aggressive form
of thoracic cancer with no known cure [1,2]. A possible reason
could be our lack of understanding of this disease at the molecular
level and a concomitant lack of good therapeutic targets [2,3].
While some published reports have focused on the molecular alter-
ations associated with the disease, what role these altered mole-
cules play in the pathogenesis of MPM is unknown [4–7].
Transcriptional proﬁling studies have reported that the fragile-X
mental retardation (FMR1) gene and downstream components of
the Jun N-terminal kinase (JNK) pathway, c-Jun and fos-1, are
up-regulated in MPM derived tissue samples [8,9]. While no possi-
ble role for FMR and the JNK pathway in MPM has been described
so far, the role of JNK pathway in tumorigenesis has been docu-
mented in several organisms including humans [10–14]. Further-
more, the JNK pathway is involved in regulation of severalimportant biological processes [15] ranging from intercellular
adhesion [16], wound healing [17], apoptosis [18], to aging [19].
Down regulation of a single gene FMR1 [20] is responsible for
the fragile X-mental retardation in humans, a disease that occurs
with a frequency of 1/5000 males and 1/6000 females [21,22].
This down-regulation of FMR1 can occur due to a variety of reasons
ranging from trinucleotide repeat expansion in the UTRs to point
mutations in the coding region of the gene to epigenetic mecha-
nisms [21]. Collectively, the phenotypes associated with misregu-
lation of the FMR1 gene are grouped into the fragile X mental
retardation syndrome or FMS [21,23]. The FMR1 gene product is
responsible for translational regulation of its target genes [24]. It
is thought that this is achieved through binding of the mRNA by
the FMR protein [23,25]. While the brain and the nervous system
have been the focus of studies on FMR function [21,23,25], recent
studies have begun to add to the knowledge of FMRs role in other
contexts. For example, it was recently demonstrated that the FMR1
gene is up-regulated in cancer cells like the hepatocellular carci-
noma where it aids in tumor migration and metastasis [26]. The
Drosophila genome consists of a single FMR gene (dFMR) [27] which
behaves similarly to its human counterpart [28]. Indeed, human
FMR1 gene can rescue Drosophila FMR mutant phenotype [29].
For this reason Drosophila has been used as an attractive genetic
model to understand FMR functions during synaptogenesis and
neuronal development.
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shown to be up-regulated in MPM [8] their roles in MPM and their
relationship to each other has not been deﬁned. Herein based on
experiments utilizing Drosophila genetics I provide clues to possi-
ble role of FMR and JNK pathway up-regulation in MPM. A novel
link between the FMR gene and the JNK pathway is also presented.
2. Materials and methods
2.1. Drosophila stocks and culture
All Drosophila stocks and crosses were raised on standard corn
meal agar medium at 25 C in vials and bottles. Both the vials
and bottles were also sprinkled with a few pellets of Red Star active
dry yeast. Vg-Gal4 (FBti0024054), Ptc-Gal4 (FBti0002124),
UAS-dFMR (FBti0026976), UAS-dsRED (FBti0018002), Tubulin-
Gal80ts (FBti0027798) are available from the Bloomington
Drosophila Stock Center and are described in the indicated Flybase
references. PucLacZ is described in Martin-Blanco et al. [30] and
Viking-GFP is described in Morin et al. [31] and was obtained from
Flytrap (http://ﬂytrap.med.yale.edu).
Genotype used in various ﬁgures and in results not presented in
ﬁgures
The complete genotype used in various ﬁgures is given below.A B 
D
Fig. 1. Overexpression of dFMR results in phenotypes indicative of cell death and an up
indicated genotype. (A) Wild-type adult drosophila wing with the space between longitu
(B) Adult drosophila wing overexpressing dFMR under the control of a Ptc-Gal4 driver. The
indicated with a bracket. (C) Adult drosophila wing overexpressing dFMR under the cont
wing imaginal discs harboring a transgene with an enhancer trap in the puckered gene (p
stained for b-galactosidse reporter gene activity which is indicated by the blue precipitate
a Ptc-Gal 4 driver and assayed for puc-lacZ activity. The b-galactosidase reporter activity
the JNK pathway. (E) Third instar wing imaginal disc overexpressing GFP (not shown)
galactosidase activity that is localized to the anterior posterior domain of Ptc-Gal4 exprFig. 1: (A) Wild type (B) w; Ptc-Gal4/+; UAS-dFMR/+ (C) w;
Vg-Gal4/+; UAS-dFMR/+ (D) w; Ptc-gal4, UAS-GFP/+; Puc LacZ/+ (E)
w; Ptc-gal4, UAS-GFP/+; Puc LacZ/UAS-dFMR.
Fig. 2. (A) w; Ptc-gal4, UAS-GFP/+; +/+ (B) w; Ptc-gal4, UAS-GFP/+;
UAS-dFMR/+.
Fig. 3. (A) w; Ptc-gal4, Viking, UAS-dsRED/+; Tubulin-Gal80ts/+ (B)
w; Ptc-gal4, Viking, UAS-dsRED/+; Tubulin-Gal80ts/UAS-dFMR.
The complete genotype of ﬂies used to test cooperation
between oncogenic RasV12 and dFMR overexpression is given
below. The stocks used have been previously described [32,33].
Control benign tumors:
yw, ey-FLP1/+ or Y; FRT40A, Tubulin-Gal80/FRT40A,
UAS-RasV12;Actin5C > y+>Gal4,UAS-GFP/+
Genotype to test cooperation between oncogenic RasV12 and
dFMR overexpression:
yw, ey-FLP1/+or Y; FRT40A,Tubulin-Gal80/FRT40A,
UAS-RasV12;Actin5C > y+>Gal4,UAS-GFP/UAS-dFMR
2.2. Beta Galactosidase assay for larval wing disc
Beta galactosidase assay was performed as described in Srivas-
tava et al. [34]. Brieﬂy, wandering third instar larvae of the correct
genotype (as described in 2.2 Fig. 1D and E) were obtained from
the cross, assessed for the presence of GFP expression under aC 
E
-regulation of the JNK pathway. A-C, whole mount of adult drosophila wing of the
dinal wing vein 3 (LV3) and longitudinal wing vein 4 (LV4) indicated with a bracket.
space between LV3 and LV4 is reduced compared to the wild type wing (in A) and is
rol of a Vg-Gal4 driver results in wing notches (arrows). (D and E) Third instar larval
uc-lacZ) capable of reporting the JNK pathway up-regulation. These discs have been
. D) Control wing imaginal disc overexpressing GFP (not shown) under the control of
is localized to the peripodial stalk (arrows) indicating the endogenous expression of
and dFMR under the control of a Ptc-Gal 4 driver. The disc has been stained for b-
ession (arrows) indicating an up-regulation of the JNK pathway.
A A’ A’’ 
B’ B’’ B 
Fig. 2. Overexpression of dFMR results in MMP1 expression and acquisition of migratory properties by overexpressing cells. All panels represent third instar larval wing
imaginal discs oriented with dorsal on the top, ventral on the bottom, anterior to the left and posterior to the right. The expression of Ptc-Gal4 along the anterior posterior
(A/P) compartment boundary is marked with Green Fluorescent Protein (GFP) from a UAS-GFP transgene (green channel) and the discs have been immunostained to localize
MMP1 protein (red channel). The merge of the two channels is shown as well. (A–A’’) Control third instar wing imaginal disc overexpressing a GFP transgene under the
control of Ptc-Gal4 driver does not up-regulate MMP1 (A’). The Ptc-Gal4 expressing cells are tightly localized to the A/P compartment boundary and do not move into the
adjacent compartment as indicated by arrows in A and A’’. (B–B’’) Wing imaginal discs overexpressing dFMR under the control of a Ptc-Gal4 driver result in up-regulation of
MMP1. Arrow points to MMP1 up-regulation in B’. The dFMR overexpressing cells are not tightly localized to the A/P compartment boundary (compared to control discs in
A–A’’) but instead migrate to the adjacent compartment as indicated by arrows in B and B’’.
A. Srivastava / FEBS Open Bio 5 (2015) 705–711 707stereo-ﬂuorescence microscope, dissected in cold 1X PBS and then
ﬁxed for 10 min in 1% Glutaraldehyde. The dissected and ﬁxed lar-
vae were washed three times in 50 mM phosphate buffer. After the
ﬁnal wash the larvae were transferred into 1 ml of staining solu-
tion with fresh X-Gal. The mixture was incubated for six hours
and then washed in 50 mM phosphate buffer. The discs were
stored in this buffer at 4 C or wing discs were dissected out from
the carcass and mounted in 70% glycerol and imaged on a Leica
Stereomicroscope.
2.3. Immunostaining
Antibody staining was performed as described in Srivastava
et al. [34]. The discs were dissected in cold 1XPBS and then trans-
ferred to a paraformaldehyde based ﬁxative solution for 10 min.
Following ﬁxation the discs were washed 2X in 1XPBTA for
20 min each. Subsequent to this the discs were placed in a blocking
solution made up of 760ul of 1XPBTA and 40uL of normal goat
serum. The discs were blocked for 30 min at room temperature
and then incubated with the primary MMP1 antibody [35]
obtained from the Developmental Studies Hybridoma Bank,
University of Iowa, Iowa, IA. The secondary antibody used was a
Cy3 conjugated anti mouse IgG obtained from Jackson Immunore-
search and used at a dilution of 1:400.2.4. Basement membrane degradation assay
Basement membrane degradation assay [34] was performed by
dissecting wing discs from ﬁve third instar larvae of the correct
genotype (w; PtcGal4, Viking-GFP, UAS-dsRED/+; UAS-dFMR1/
Tubulin-Gal80ts), raised at 18 C and then shifted to 25 C for
48–72 h. The dissected discs were ﬁxed, mounted in Vectashield
mounting media (Vector Laboratories) and then imaged on a Zeiss
LSM510 Confocal Microscope using the green and the red channels
in a sequential setting. The Z-stack obtained was further processed
to generate orthogonal XZ sections and assess basement mem-
brane degradation. The observed BM degradation was most seen
in the hinge region of the wing disc and was incompletely
penetrant.
3. Results
3.1. Overexpression of dFMR results in cell death and up-regulation of
the JNK pathway
To better understand the role of FMR in MPM and to mimic the
FMR up-regulation observed in MPM I chose to over-express
the dFMR gene in the developing Drosophila wing disc using the
UAS-Gal4 system [36]. Overexpression of dFMR in different regions
Fig. 3. Basement membrane degradation occurs as a result of dFMR overexpression. A–B, Confocal XZ sections from wing imaginal discs where the basement membrane (BM)
is labelled (green or white channels) with a protein trap insertion in the Drosophila collagen IV gene, viking. The domain of Ptc-Gal4 expression is marked with the Gal4 driven
expression of dsRED (red channel). (A) XZ section from control wing imaginal disc overexpressing dsRED under the control of a Ptc-Gal4 driver. Note that the BM is intact
where Gal4 is expressed. A’ and A’’ represent BM label in green channel and white channel for improved contrast. (B) XZ section from a wing imaginal disc overexpressing
dFMR under the control of the Ptc-Gal4 driver and marked for BM as described in A. Note that the BM is discontinuous and degraded where dFMR is expressed (arrow in B’).
Individual green and white channels are provided for better contrast and visualization.
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C). For example, overexpression of dFMR along the anterior poste-
rior compartment border (using Ptc-Gal4 driver) resulted in less
tissue in the region of overexpression between wing vein 3 and
wing vein 4 (bracketed region in Fig. 1B compared to 1A, n = >50
ﬂies with complete penetrance). Similarly, overexpression of dFMR
in the wing margin (using Vg-Gal4 driver) resulted in wing notches
(Fig. 1C). These phenotypes conﬁrm previously reported pheno-
types where the dFMR overexpressing cells were shown to be
apoptotic as judged by their incorporation of Acridine Orange [27].
Because cell death can be caused by up-regulation of the JNK
pathway [37], I reasoned that the dFMR overexpressing cells in
the wing imaginal disc could be up-regulating the JNK pathway.
The up-regulation of puckered (puc) gene has been exploited as a
reliable readout of the status of JNK pathway activity in Drosophila
[30,38]. This is because activation of the JNK pathway is associated
with an increased expression of the dual speciﬁcity phosphatase
encoded by the puc gene. The puc assay has been facilitated by
the existence of an enhancer trap insertion in the puc gene (PucLacZ)
with b-galactosidase as the reporter [30,38]. In control wing discs
(Fig. 1D, arrowheads) the b-galactosidase reporter from the PucLacZ
is localized to a region of the wing disc called the peripodial stalk
(arrowheads in Fig. 1D). Overexpression of dFMR gene along the
anterior posterior compartment border [39] of the wing disc (using
the Ptc-Gal4 driver) and in a genetic background that also con-
tained PucLacZ resulted in an increased expression of the JNK path-
way (arrows in Fig. 1E compared to arrowheads in 1D).3.2. Overexpression of dFMR results in up-regulation of MMP
Having established that the dFMR gene can up-regulate the JNK
pathway I hypothesized that dFMR expression could also result in
the up-regulation of MMP. This was based on the observation that
JNK signaling regulates the expression of MMPs [12,34]. To test my
hypothesis I overexpressed dFMR in wing discs using the Ptc-Gal4
driver and simultaneously immunostained these discs with an
antibody directed towards the Drosophila MMP1 (see materials
and methods).The domain of Ptc-Gal4 expression in these discs
was marked with Green Fluorescent Protein (GFP) expression from
a UAS-GFP transgene. Control wing discs (Fig. 2A) expressing GFP
and stained for MMP protein expression resulted in no MMP
expression in the domain of dFMR expression (Fig. 2A–A’’). The
domain of expression of GFP in these cells was tightly localized
to the region of Ptc-Gal4 expression with sharp boundaries (arrows
in Fig. 2A, A’’). However, overexpression of dFMR in the wing disc
using the Ptc-Gal4 driver resulted in robust MMP expression
(arrows in Fig. 2B’, B’’ compared to Fig. 2A’, A’’) in a cell autono-
mous and non-cell autonomous manner. Furthermore, the cells
overexpressing dFMR and consequently MMP were not restricted
to the tight domain of GFP expression observed in control discs
(arrows in Fig. 2A, A’’). Instead, the dFMR overexpressing cells
appear to leave the domain of Ptc-Gal4 expression (as judged by
GFP labeled cells in Fig. 2B pointed with arrows) and migrate into
the opposite posterior compartment (arrows in Fig. 2B–B’’). This
phenotype has been previously observed in cells that display
Malignant Pleural 
Mesothelioma Phenotypes 
Up-regulation 
of FMR 
Up-regulation 
of fos-1 
Genetic Alterations 
associated with MPM 
? 
? ? 
Malignant Pleural Mesothelioma 
Up-regulation 
of FMR 
Up-regulation 
of JNK 
pathway
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Fig. 4. A model proposing how FMRmay contribute to tumorigenesis in MPM. (A) It
is known that genetic alterations in MPM result in FMR and the JNK pathway up-
regulation. The relationship between FMR and the JNK pathway and the role of FMR
in tumorigenesis was unknown (depicted by question marks). (B) A proposed model
based on preliminary ﬁndings in this study illustrates how FMR could contribute to
tumorigenesis in MPM. Brieﬂy, overexpression of FMR results in up-regulation of
the JNK pathway which in turn up-regulates MMP leading to degradation of the BM
and thereby possibly contributing to the MPM phenotype. The possibility of JNK and
FMR acting through other mechanisms to effect tumorigenesis cannot be ruled out
and is indicated with arrows and boxed question marks. Boxed question marks also
signify proposed, speculative connections for which experimental veriﬁcation is
required.
A. Srivastava / FEBS Open Bio 5 (2015) 705–711 709migratory behavior in the Drosophila wing disc [40]. Based on the
previous observations it is inferred that cells that overexpress
dFMR up-regulate the JNK pathway and an MMP and in the process
acquire migratory properties that allow them to move away from
their primary site. The acquisition of migratory properties and
the degradation of BM is an important turning point in tumor cells
becoming metastatic [41]. I next asked if dFMR overexpression can
lead to the degradation of BM.
3.3. Overexpression of dFMR results in degradation of the BM
To test the idea that dFMR overexpression can lead to BM degra-
dation I overexpressed dFMR using the Ptc-Gal4 driver in a genetic
background that also harbored a GFP protein trap [31] transgene in
the viking gene (see materials and methods) [34]. One of the major
constituents of BM is the Collagen IV protein [42] which is encoded
by the viking gene in Drosophila. The protein trap in the viking gene
also labels the BM with GFP. Overexpression of dFMR in wing discs
using the Ptc-Gal4 driver resulted in modest degradation of the BM
(arrows in Fig. 3). This degradation of the BM was incompletely
penetrant and primarily observed in the hinge region of the wing
disc. A reason for the incomplete penetrance could be the variable
expression of the transgenes with maximal expression of dFMR by
Ptc-Gal4 occurring in the hinge region.
3.4. Overexpression of dFMR does not cooperate with activated RasV12
It has been shown in Drosophila that JNK pathway cooperates
with an activated oncogene, RasV12, during tumor growth and
metastasis [10]. Furthermore, the JNK pathway is also misregu-
lated in human tumors [11,13]. Because FMR up-regulation leads
to an up-regulation of the JNK pathway, it is possible that the
FMR up-regulation in MPM collaborates with other oncogenes or
mutations in tumor suppressor genes to bring about the metastatic
effect associated with MPM. One possibility could be cooperation
between FMR overexpression and the overexpression of RasV12
(Ras is frequently affected in human tumors). To test this possibil-
ity I utilized the MARCM system [43] in Drosophila to overexpress
dFMR in clones of GFP labeled cells also simultaneously overex-
pressing RasV12. No over proliferation or migration of tumor tissue
to contiguous organs was observed in these larvae when compared
to the control RasV12 only expressing larvae. These results suggest a
lack of cooperation between overexpression of dFMR and RasV12
(data not shown).
4. Discussion
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer
where molecular alterations and their role in MPM pathogenesis
are not well understood [3–5,8]. It has been known that FMR1
and the JNK pathway are up-regulated in MPM derived tissue sam-
ples [8] however their role in MPM and their relationship to each
other was unknown (Fig. 4A, question marks). In this study, using
Drosophila genetics, a set of data are presented that provide a novel
link between FMR and the JNK pathway and offer clues to a possi-
ble role of these two molecules in MPM. First, it is demonstrated
that overexpression of dFMR can up-regulate the JNK pathway
(Fig. 1D-E) as assessed by the expression of the dual speciﬁcity
phosphatase enhancer trap, pucLacZ. Second, the FMR overexpress-
ing cells acquire migratory properties as they overcome the restric-
tive barriers imposed by the organ compartment boundary and
move to the posterior compartment of the wing disc (Fig. 2). This
acquisition of migratory properties by tumor cells is an important
event in tumor metastasis and could be playing a similar role in
MPM. Third, dFMR up-regulation results in up-regulation of an
MMP (Fig. 2) and degradation of the BM (Fig. 3). Because a linkbetween JNK pathway up-regulation and tumorigeneis has been
well established in Drosophila [10,12,34] and in hepatocellular car-
cinoma and skin cancer in mice and humans [11,14] and because
up-regulation of MMP and the degradation of BM are important
events during tumor metastasis [41], it is attractive to propose that
through its up-regulation of the JNK pathway, FMR possibly con-
tributes to tumorigenesis in MPM (Fig. 4). However, this connec-
tion is speculative and remains to be experimentally veriﬁed.
Whether the up-regulation of JNK by FMR is direct or indirect
remains to be seen and the possibility of FMR acting through non
JNK mediated mechanisms in MPM cannot be ruled out either
(Fig. 4B, question marks).
Because JNK pathway and RasV12 collaborate during tumorigen-
esis in Drosophila [10], it was an interesting possibility that FMR
overexpression and RasV12 may collaborate as well by way of JNK
pathway up-regulation in response to FMR overexpression. My
results however, failed to demonstrate a collaboration between
these two genes. A possible reason could be that Ras is very rarely
misregulated in MPM patients [5] but instead most of the MPM
patients have a defect in neuroﬁbromatosis 2 gene (NF2) which is
a tumor suppressor gene and works through the recently identiﬁed
Hippo signaling pathway [44]. It is possible that FMR cooperates
with NF2 mutations to bring about the tumorigenic effects seen
in MPM. Future efforts could focus on this hypothesis and utilize
mutations in the Drosophila NF2 genemerlin to test the cooperation
between FMR overexpression and NF2 mutations.
The fact that Fragile-X Mental Retardation Syndrome (FMS)
patients are less likely to develop tumors is intriguing [45]. A pos-
sible explanation comes from studies where FMS patients display a
mild reduction in the ligand for the b-catenin pathway (an impor-
tant oncogenic pathway) [46]. Furthermore, in hepatocellular car-
cinoma [47] and breast cancer tissues [26] the FMR1 gene has
been found to be highly up-regulated. It has been proposed that
the FMR1 encoded FMR protein regulates cell adhesion, epithelial
mesenchymal transition in these breast cancer patients, both of
which are important events in tumor metastasis [26]. A decrease
of FMR1 in FMS patients would result in down-regulation of the
710 A. Srivastava / FEBS Open Bio 5 (2015) 705–711above mentioned tumor causing effects and thereby make tumor
formation and metastasis difﬁcult. Future studies could focus on
exploring these links as causative reasons for preventing tumorige-
nesis in FMS patients.
The data presented by me in this study offer another possible
explanation for why FMS patients are less likely to develop tumors.
In FMS patients the FMR1 gene is either silenced or mutated. The
ﬁndings in this study of a ‘‘FMR-JNK’’ connection and the knowl-
edge of FMR [26] and JNK pathway’s involvement in hepatocellular
carcinoma [11] suggest that the ‘‘FMR-JNK’’ connection could also
be active in hepatocellular carcinoma, supporting its progression.
Future studies could test this idea by knocking down FMR1 and
observing the resultant suppression of hepatocellular carcinoma.
My ﬁndings, taken together, provide a unique link between FMR
and the JNK pathway (Fig. 4) and help offer possible roles the FMR
and JNK pathway activation might play during MPM. It also offers a
possible reason why FMS patients are resistant to tumor formation.
I also demonstrate that dFMR and RasV12 do not collaborate during
tumorigenesis, instead the possibility of a collaboration between
FMR1 overexpression and NF2 mutations is open and should be
investigated as one of the collaborative molecular events during
the formation of MPM.
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